Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.55M | 6.19M | 4.85M | 4.67M | 4.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.35M | 31.12M | 64.02M | 49.50M | 27.79M |
| Operating Income | -34.35M | -31.12M | -64.02M | -49.50M | -27.79M |
| Income Before Tax | -32.78M | -29.61M | -62.50M | -47.71M | -26.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.78M | -29.61M | -62.50M | -47.71M | -26.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.78M | -29.61M | -62.50M | -47.71M | -26.18M |
| EBIT | -34.35M | -31.12M | -64.02M | -49.50M | -27.79M |
| EBITDA | -34.29M | -31.05M | -63.93M | -49.41M | -27.71M |
| EPS Basic | -0.31 | -0.33 | -0.73 | -0.61 | -0.41 |
| Normalized Basic EPS | -0.20 | -0.21 | -0.46 | -0.38 | -0.26 |
| EPS Diluted | -0.31 | -0.33 | -0.73 | -0.61 | -0.41 |
| Normalized Diluted EPS | -0.20 | -0.21 | -0.46 | -0.38 | -0.26 |
| Average Basic Shares Outstanding | 104.38M | 90.26M | 85.18M | 78.32M | 64.03M |
| Average Diluted Shares Outstanding | 104.38M | 90.26M | 85.18M | 78.32M | 64.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |